The Executive Committee of the ECOG-ACRIN Cancer Research Group is one of two committees that govern the Group under the leadership of the Group Co-Chairs (the other is the Principal Investigator Committee). The Executive Committee meets quarterly to monitor the scientific and operational progress of the Group and oversee strategic planning, finances, resource allocation, and related matters. The committee also frequently recommends topics to include on agendas for PI Committee meetings and the Group Co-Chairs work through this committee to enact policy and resolve any organizational issues that may arise from time to time.

The Executive Committee consists of the Executive Leadership, individuals elected by the Principal Investigator (PI) Committee, and individuals appointed by the Group Co-Chairs to represent the interests of defined constituent groups. The following individuals, stratified by category (ie, executive, elected, and appointed members), are the current members of the Executive Committee.

Executive Members

Group Co-Chair
Peter J. O’Dwyer, MD
University of Pennsylvania/Penn Medicine Abramson Cancer Center
Mitchell D. Schnall, MD, PhD
Group Co-Chair
Mitchell D. Schnall, MD, PhD
University of Pennsylvania/Hospital of the University of Pennsylvania
Constantine A. Gatsonis, PhD
Group Statistician, Imaging
Constantine A. Gatsonis, PhD
Brown University
Robert J. Gray, PhD
Group Statistician. Therapeutic
Robert J. Gray, PhD
Dana-Farber Cancer Institute
Joseph Aisner, MD
Group Vice Chair
Deputy Chair, Policy and Implementation
Al B. Benson III, MD, FACP, FASCO
Northwestern University and the Robert H. Lurie Comprehensive Cancer Center
Bruce J. Giantonio, MD, FACP
Group Executive Officer
Bruce J. Giantonio, MD, FACP
Harvard Medical School and Massachusetts General Hospital
Donna M. Marinucci
Executive Director
Donna M. Marinucci, BSMT
Drexel University

Elected Members

Barry A. Siegel, MD
Scientific Main Members Representative
Barry A. Siegel, MD
Washington University in St. Louis
brad-s-kahl
Academic-based Standing Main Members Representative
Heather A. Wakelee, MD
Stanford University and the Stanford Cancer Institute
Kurt R. Oettel, MD
Community-based Standing Main Members Representative
Kurt R. Oettel, MD
Wisconsin NCORP
Gundersen Lutheran Health System
Affiliate Members Representative
Matthias Weiss, MD
Mayo Clinic Health System-Franciscan Healthcare

Appointed Members

 

Lynne Wagner
Deputy Chair, Cancer Control and Outcomes Program
Lynne I. Wagner, PhD
Wake Forest School of Medicine
Suresh S. Ramalingam, MD

Deputy Chair, Therapeutic Studies Program

Suresh S. Ramalingam, MD
Emory University and the Winship Cancer Institute
 Keith T. Flaherty, MD
Deputy Chair, Biomarker Sciences Program
Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center
Stanley R. Hamilton, MD
Deputy Chair, Laboratory Sciences Program
Stanley R. Hamilton, MD
City of Hope

 

Joseph Aisner, MD
U01 Grant Holders Liaison
Joseph Aisner, MD
In Transition
Michael A. Carducci, MD, FACP
Specialized Programs of Research Excellence (SPOREs) Liaison
Michael A. Carducci, MD, FACP
Johns Hopkins University and The Sidney Kimmel Comprehensive Cancer Center
Selina M. Luger, MD
Elderly Populations Representative
Efrat E. Dotan, MD
Fox Chase Cancer Center
Edith P. Mitchell, MD, FACP
Underserved Populations Representative
Edith P. Mitchell, MD, FACP
Thomas Jefferson University and the Sidney Kimmel Cancer Center at Thomas Jefferson University
George W. Sledge Jr, MD
Cancer Centers Liaison
George W. Sledge Jr., MD
Stanford University and the Stanford Cancer Institute
Selina M. Luger, MD
Health Equity Representative
Melissa A. Simon, MD, MPH
Northwestern University and the Robert H. Lurie Comprehensive Cancer Center
Edith P. Mitchell, MD, FACP
Cancer Research Advocate
Mary Lou Smith, JD, MBA
Research Advocacy Network
George W. Sledge Jr, MD
Research Associates Representative
Wendy J. Smith, BS, RTRCV, CCRP
Rhode Island Hospital

Contact

Direct inquiries about this committee to:

Jean MacDonald, MPH
Deputy Executive Director, Operations
ECOG-ACRIN Cancer Research Group
Phone: 857.504.2900
Email

Return to Top | Return to Governance